$11.66
9.86% today
Nasdaq, Sep 25, 05:48 pm CET
ISIN
US4834971032
Symbol
KALV

KalVista Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

KalVista Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
94%
Hold
6%

KalVista Pharmaceuticals, Inc. Price Target

Target Price $30.60
Price $12.93
Potential
Number of Estimates 11
11 Analysts have issued a price target KalVista Pharmaceuticals, Inc. 2026 . The average KalVista Pharmaceuticals, Inc. target price is $30.60. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 15 Analysts recommend KalVista Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the KalVista Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the KalVista Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '25 2026
Estimates

12 Analysts have issued a sales forecast KalVista Pharmaceuticals, Inc. 2026 . The average KalVista Pharmaceuticals, Inc. sales estimate is

$39.8m
Unlock
. This is
2,684.48% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$73.9m 5,070.91%
Unlock
, the lowest is
$13.1m 818.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2027
$125m 213.43%
Unlock
2028
$236m 88.89%
Unlock
2029
$372m 57.66%
Unlock
2030
$482m 29.66%
Unlock
2031
$579m 20.15%
Unlock
2032
$657m 13.43%
Unlock

3 Analysts have issued an KalVista Pharmaceuticals, Inc. EBITDA forecast 2026. The average KalVista Pharmaceuticals, Inc. EBITDA estimate is

$-168m
Unlock
. This is
61.96% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-173m 66.73%
Unlock
, the lowest is
$-162m 55.61%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

EBITDA Margin

12 KalVista Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average KalVista Pharmaceuticals, Inc. net profit estimate is

$-185m
Unlock
. This is
80.98% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-164m 60.60%
Unlock
, the lowest is
$-200m 95.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2027
$-73.0m 60.60%
Unlock
2028
$-30.6m 58.14%
Unlock
2029
$80.5m 363.34%
Unlock
2030
$153m 90.70%
Unlock
2031
$194m 26.57%
Unlock
2032
$228m 17.61%
Unlock

Net Margin

2027
-58.47% 87.43%
Unlock
2028
-12.96% 77.83%
Unlock
2029
21.64% 266.98%
Unlock
2030
31.84% 47.13%
Unlock
2031
33.54% 5.34%
Unlock
2032
34.78% 3.70%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '25 2026
Estimates
P/E negative
EV/Sales 14.92

12 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast for earnings per share. The average KalVista Pharmaceuticals, Inc. EPS is

$-3.68
Unlock
. This is
92.67% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-3.27 71.20%
Unlock
, the lowest is
$-3.98 108.38%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2027
$-1.45 60.60%
Unlock
2028
$-0.61 57.93%
Unlock
2029
$1.60 362.30%
Unlock
2030
$3.05 90.63%
Unlock
2031
$3.86 26.56%
Unlock
2032
$4.54 17.62%
Unlock

P/E ratio

Current -6.77 97.47%
2026
-3.51 48.15%
Unlock
2027
-8.92 154.13%
Unlock
2028
-21.30 138.79%
Unlock
2029
8.09 137.98%
Unlock
2030
4.24 47.59%
Unlock
2031
3.35 20.99%
Unlock
2032
2.85 14.93%
Unlock

Based on analysts' sales estimates for 2026, the KalVista Pharmaceuticals, Inc. stock is valued at an EV/Sales of

14.92
Unlock
and an P/S ratio of
16.41
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 415.47
2026
14.92 96.41%
Unlock
2027
4.76 68.09%
Unlock
2028
2.52 47.06%
Unlock
2029
1.60 36.57%
Unlock
2030
1.23 22.88%
Unlock
2031
1.03 16.77%
Unlock
2032
0.90 11.84%
Unlock

P/S ratio

Current
2026
16.41 96.41%
Unlock
2027
5.23 68.09%
Unlock
2028
2.77 47.06%
Unlock
2029
1.76 36.57%
Unlock
2030
1.36 22.88%
Unlock
2031
1.13 16.77%
Unlock
2032
0.99 11.84%
Unlock

Current KalVista Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked Sep 12 2025
Needham
Locked
Locked
Locked Sep 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 08 2025
JMP Securities
Locked
Locked
Locked Jul 08 2025
Leerink Partners
Locked
Locked
Locked Jul 07 2025
Needham
Locked
Locked
Locked Apr 08 2025
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
Sep 12 2025
Locked
Needham:
Locked
Locked
Sep 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 08 2025
Locked
JMP Securities:
Locked
Locked
Jul 08 2025
Locked
Leerink Partners:
Locked
Locked
Jul 07 2025
Locked
Needham:
Locked
Locked
Apr 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today